---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-060195"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:51:35.598178+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Apogee reports Q1 net loss $32.1M, cash $816M, advances pipeline with Phase 2 start for APG777 and $483M raise

## Summary
- Net loss $32.1M vs $12.5M YoY; R&D expenses $28.7M (up from $8.5M) as pipeline progresses.
- Cash, equivalents and marketable securities $816.2M; runway into early 2028.
- Completed upsized public offering raising $483M gross proceeds at $62.00/share.
- Initiated Phase 2 trial of APG777 (IL-13) in atopic dermatitis; proof-of-concept data expected 2H 2025.
- Dosed first participant in Phase 1 trial of APG808 (IL-4Rα); interim data expected 2H 2024.

## SEC filing metadata
- accession: 0001104659-24-060195
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000110465924060195/0001104659-24-060195-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000110465924060195/tm2414075d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-060195
- JSON: https://secwatch.observer/filing/0001104659-24-060195.json
- Plain text: https://secwatch.observer/filing/0001104659-24-060195.txt

## Key facts
- Earnings Releases
  Apogee Therapeutics, Inc. reported financial results for first quarter 2024.
  - Period: first quarter 2024
  - Result: reported results
  source text: On May 13, 2024, Apogee Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1974640/000110465924060195/0001104659-24-060195-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.